The ROR family of proteins includes ROR1 and ROR2 – receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and never in healthy adult tissue. This makes it a strong therapeutic target for the treatment of several types of cancer.
Many different therapies are under development that target ROR1, including Oncternal’s Cirmtuzumab.
Domains of the ROR1 Receptor Tyrosine Kinase
ROR1’s extracellular domain has three well-defined domains. These are a frizzled domain, a kringle domain and an immunoglobin-like (Ig) domain (Borcherding et al., 2014). It has been found that the use of antibodies, which target the different domains of ROR1, for the treatment of leukemia cell lines results in a significantly different efficacy (Daneshmanesh et al., 2013).
ACROBiosystems can supply researchers with a full range of human model ROR1 proteins. These include products for the complete ECD of all of ROR1 domains, and also for its individual domains.
As well as the domain proteins, ACROBiosystems also provide two pre-biotinylated forms of ROR1 (ECD) that have been produced using avitag technology.
This method involves the conjugation of biotin onto an Avitag that is located at the protein’s C-terminus. This location-specific labeling technique provides several benefits when compared to conventional NHS-labeling – the native structure of the protein is retained and the labeling bioactivity and efficiency is completely uniform.
Pre-Biotinylated ROR1 Proteins from ACROBiosystems
ACROBiosystems pre-biotinylated ROR1 proteins have been used to screen for anti-ROR1 mAbs. In addition, these proteins are also available for animal research using rat and mouse models.
ROR1 shares 58% of its homology with ROR2, meaning cross-reactivity with ROR2 can be a problem when using an anti-ROR1 reagent. Comparative analysis must often be employed to rule out this problem. To help solve this problem, ACROBiosystems supplies the following ROR2 proteins for use in human and murine models.
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
To respond to coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantity.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.